A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

NCT06139406 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG: JNJ-87801493
DRUG: JNJ-80948543
DRUG: JNJ-75348780

Sponsor

Janssen Research & Development, LLC